NCT00697554View on ClinicalTrials.gov

Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Pre-liver Transplant Patients 18 Years of Age

PHASE3CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

January 31, 2000

Primary Completion Date

May 31, 2002

Conditions
Hepatitis B
Interventions
BIOLOGICAL

HBV-MPL vaccine 208129

2-dose primary vaccination followed by 1 booster vaccination by intramuscular injection

BIOLOGICAL

Engerix™-B

3-dose primary vaccination followed by 1 booster vaccination by intramuscular injection of double doses

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00697554 - Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Pre-liver Transplant Patients 18 Years of Age | Biotech Hunter | Biotech Hunter